Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Prolonging fixation time of an alternative fixative to formalin for dermatological samples using standard laboratory protocols

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. JAK2-tree: a simple CBC-based decision rule to guide appropriate JAK2 V617F mutation testing

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Hypoxia-inducible factor 1α predicts recurrence in high-grade soft tissue sarcoma of extremities and trunk wall

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Clinical Validation of the Fully Automated NeuMoDx HPV Assay for Cervical Cancer Screening

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. VALCOR: a protocol for the validation of SARS-corona virus-2 assays

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Differentieret implementering af HPV-baseret screening i dansk livmoderhalskræftscreening

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

AIM: The Papilloplex high-risk human papillomavirus (hrHPV) test (Genefirst, Oxford, UK) is a single tube real-time HPV test which provides multiplex detection and separate identification of 14 hrHPV types. Here, we present the clinical validation of the test in SurePath samples in comparison to a clinically validated reference test, the GP5+/6+Enzyme ImmunoAssay (GP5+/6+EIA) using the VALGENT (VALidation of HPV GENotyping Tests) framework.

METHODS: Clinical performance was assessed using 998 unselected, cervical screening samples enriched with 297 cytologically abnormal specimens (100 atypical squamous cells of unspecified significance, 100 low-grade squamous intraepithelial lesions, 97 high-grade squamous intraepithelial lesions). Cases were defined as women diagnosed with histologically confirmed cervical intraepithelial neoplasia two or more (≥CIN2, N=119) and controls defined as women with two subsequent negative cytology results (N=834).

RESULTS: The Papilloplex HR-HPV test has non-inferior sensitivity for detection of cervical precancer (p=0.0001 for ≥CIN2 and p=0.0005 for ≥CIN3) and non-inferior specificity, compared with GP5+/6+EIA (pni=0.0167)). The assay also showed excellent or good agreement for overall hrHPV and nearly all individual HPV types as compared with GP5+/6+EIA/Luminex.

CONCLUSION: The Papilloplex HR-HPV applied on cervical specimens stored in SurePath medium fulfils the international clinical accuracy criteria for use in cervical cancer screening.

OriginalsprogEngelsk
Artikelnummer207864
TidsskriftJournal of Clinical Pathology
Sider (fra-til)1-5
Antal sider5
ISSN0021-9746
DOI
StatusE-pub ahead of print - 15 nov. 2021

Bibliografisk note

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

ID: 69064653